Rituxan CD20 Binding Assays
BioOutsource offers a range of off-the-shelf Rituxan CD20 binding assays to support Rituxan biosimilar manufacture, process development, characterization and comparability studies. We offer industry leading Rituxan comparability and Rituxan characterization services and these can be adapted to your product, if required.
Rituxan (rituximab) mediates its activity through the interaction with CD20. Rituxan (rituximab) binds this protein with high affinity and mediates a number of different outcomes including inhibition of proliferation as well as recruitment of the effector cells of the immune system. Therefore, CD20 binding by Rituxan, as with all antibody-antigen interactions, represents one of the key quality attributes of the Rituxan (rituximab) molecule.
CD20 binding assays can be performed using a wide variety of different assay platforms and on each platform, these CD20 binding assays can be conducted using different binding assay designs. BioOutsource has developed the following Rituxan CD20 binding assay:
Rituxan CD20 Binding ELISA by Electrochemiluminescence (MSD)
BioOutsource offers Rituxan CD20 binding assays using an upgraded version of the traditional ELISA on the Mesoscale Discovery (MSD) platform to report the relative binding of biosimilar and innovator Rituxan material as a percentage of a designated reference lot with comprehensive parallelism assessments. BioOutsource works closely with our clients and can adapt this method for performance as a traditional ELISA platform, where required.